International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.
about
Intellectual developmental disorders: towards a new name, definition and framework for "mental retardation/intellectual disability" in ICD-11Prescribing psychotropic drugs to adults with an intellectual disabilityMental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort studyA Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple AntidepressantPrimary care of adults with developmental disabilities: Canadian consensus guidelines.Training on intellectual disability in health sciences: the European perspectiveIntellectual disability and mental health problems: a qualitative study of general practitioners' views.Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.Challenging behavior and related factors in people with intellectual disability living in residential care centers in Israel.Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice.Polypharmacy in the treatment of subjects with intellectual disability.Framing of scientific knowledge as a new category of health care research.Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.Mental illness, problem behaviour, needs and service use in adults with intellectual disability.Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study.Successful management of difficult-to-treat aggression with low-dose propranolol in a patient with intellectual disability: a case report.Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability.An Exploration of Costs of Community-Based Specialist Health Service Provision for the Management of Aggressive Behaviour in Adults with Intellectual Disabilities.Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.Soins primaires aux adultes ayant une déficience développementale: Lignes directrices consensuelles canadiennes.Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability.Improving recording of capacity to consent and explanation of medication side effects in a psychiatric service for people with learning disability: audit findings.Soins primaires aux adultes ayant des déficiences intellectuelles et développementales: Lignes directrices consensuelles canadiennes de 2018.Primary care of adults with intellectual and developmental disabilities: 2018 Canadian consensus guidelines.Recognition and treatment of mood dysregulation in adults with intellectual disability
P2860
Q24635210-916D5BB8-8445-4C27-9C26-A3518D065B16Q28075485-08ABC466-D712-4A71-8EDF-EC3195EB8179Q28608168-FF3BB92E-8E9A-4AB3-8C30-23543F8C1121Q34521320-5763087C-492C-45F6-B23E-9958FA954971Q34978203-C3BE9B9F-A8C5-4FDD-9583-07BEE4F03697Q35101155-2A30C2BF-B06D-4628-9CC4-EFC3BBA6BBC9Q36730157-754E60A6-923F-4F51-9096-695DF72A41A5Q36773303-105E29AF-A5F1-4F1B-BFCE-68784EF3D390Q37087389-0B120026-C19D-4A7D-8F92-4A290BE4E6D0Q37372528-99FF65C2-93E9-4034-BEE3-DF9218BBEEF4Q37517352-91F023DA-652D-4D86-95F1-7DA92F3E01E7Q38214474-228A2C8A-B1D3-4BF2-A2A5-A5FB43530A8BQ38271021-9D6A4816-BB2A-4702-8DD9-38688CBC9B1BQ38312346-5229204C-5CBA-4AA7-B614-B5C528BD74F9Q38764687-EDDFA28A-57CB-4148-AD0D-FF6471929006Q39019088-E014AF70-0372-4377-B006-8A9A0BEDE889Q41767521-364E670D-DE0C-4651-A80A-0161A6D24436Q47708555-EA333E60-D182-4A08-8CE0-0339CCC6423AQ48838438-0ED90847-7531-449D-B4B4-78E5BD94F6BEQ50305958-9AD55D6D-060B-42FC-91CA-D885E8FF9555Q50351273-B7BCAD97-3730-47A9-A13C-9F6C7A8AC44CQ50703449-63E4571F-7233-42B4-B354-01353CE3D1C8Q50794505-849923D6-1B6D-473C-BA79-663B6E42920CQ55026333-F98AFCEA-39F3-4438-82E2-12F98B6ACF87Q55128329-F33370F7-65F3-4DCC-B649-63322C5680EAQ58567935-170CA31F-0A21-4CED-B456-A01CB5E98635
P2860
International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
International guide to prescri ...... ith intellectual disabilities.
@en
International guide to prescri ...... ith intellectual disabilities.
@nl
type
label
International guide to prescri ...... ith intellectual disabilities.
@en
International guide to prescri ...... ith intellectual disabilities.
@nl
prefLabel
International guide to prescri ...... ith intellectual disabilities.
@en
International guide to prescri ...... ith intellectual disabilities.
@nl
P2093
P2860
P1433
P1476
International guide to prescri ...... ith intellectual disabilities.
@en
P2093
Elspeth Bradley
Guideline Development Group of the WPA Section on Psychiatry of Intellectual Disability
Henry Kwok
Jarret Barnhill
Jennifer Torr
Shoumitro Deb
P2860
P304
P356
10.1002/J.2051-5545.2009.TB00248.X
P407
P577
2009-10-01T00:00:00Z